Develop business Strategies Of Acute Myeloid Leukemia Market 2024
"The
Latest Research Report OpportunityAnalyzer: Acute Myeloid Leukemia
(AML) - Opportunity Analysis and Forecasts to 2024 provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
About
Acute Myeloid Leukemia Market
Acute myeloid (myelogenous,
myelocytic) leukemia (AML) is a rapidly progressing blood cancer with
an extremely poor overall prognosis. AML predominantly affects the
elderly population and this subgroup of patients has an exceptionally
high level of unmet needs. GlobalData estimates the 2014 sales for
AML at approximately $342 million across the 7MM covered in this
report. The market will increase by almost three-fold over the
forecast period, reaching $932 million in 2024 at a CAGR of 10.5%.
This growth will be driven by an increase in incident cases of AML as
well as the approval and uptake of premium-priced products, such as
FLT3 kinase inhibitors (quizartinib and midostaurin), a PI3 kinase
inhibitor (volasertib) and new formulations of existing
chemotherapies such as Vyxeos (CPX-351), guadecitabine and CC-486.
GlobalData expects, by the end of the forecast period, new branded
therapies Vyxeos, volasertib and CC-486 will dominate the market
along with generic azacitidine. The AML pipeline is weak in terms of
efficacy; however, GlobalData expects none of these drugs to have a
major impact on the overall AML market. The challenge for new
entrants into the AML market is to meet the critically high unmet
needs of AML patients and improve overall survival. One of the
opportunities for the companies is to work cooperatively to develop
therapies that work in combination with chemotherapy backbone.
Highlights
Key Questions Answered
- For over forty years, there has
been no major advances in the treatment for AML. The AML space is
filled with excitement because the first targeted FLT3 kinase
inhibitor therapies are expected to change the treatment landscape.
What will be the impact of these newly approved drugs on AML sales?
- With the unmet needs of AML
patients remaining critically high, what R&D strategies and
opportunities are being used by drug makers to remain competitive?
Get Sample Copy Of This Report
@ https://www.marketresearchreports.biz/sample/sample/631642
- The survival of patients with
AML remains dismal, especially for those who do not respond to
first-line chemotherapies. Therefore, there are considerably high
unmet needs within the indication. What are the main unmet needs in
this market? Will the drugs under development fulfil the unmet needs
of the AML market?
Key Findings
- One of the main drivers in the
expansion of the AML market will be the launch of premium-priced
targeted therapies (FLT3 kinase inhibitors, PI3 kinase inhibitor and
reformulations of chemotherapy drugs). for patients with extremely
high unmet needs, both the elderly and refractory/relapsed
population. These drugs will gradually be used in combination with or
replace cheaper, generic, cytarabine-based chemotherapy regimens.
- Another driver will be the few
players in the AML market, and that current therapies are largely
considered to be ineffective. Therefore, there is ample room for new
market entrants. A major driver will also be that a growing incident
elderly AML population, particularly in the US, will increase the
number of treatable AML patients.
- Companies are focusing on the
development of combination therapies, trying to improve the complete
remission rate and duration of remission.
- One of the largest unmet needs
is a need for efficacious treatment options for elderly AML patients.
The majority of AML patients do not have FLT3 mutations, and are
therefore ineligible for FLT3 inhibitor treatments. Other unmet needs
include therapies for refractory/relapsed disease.
Scope
- Overview of AML, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
disease management.
- Annualized AML therapeutics
market revenue, cost of therapy per patient, and treatment usage
patterns in four patient segments (including, young patients, elderly
patients, refractory/relapsed patients and FLT3 mutated patients),
forecast from 2014 to 2024.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, clinical trial mapping and implications for the AML
therapeutics market.
- Pipeline analysis: comprehensive
data assessing emerging trends and mechanisms of action under
development for different lines of therapy. The most promising
candidate in Phase III development is profiled.
- Analysis of the current and
future market competition in the global AML therapeutics market.
Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline.
- Develop business strategies by
understanding the trends shaping and driving the global AML
therapeutics market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the global melanoma
therapeutics market in the future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analysing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Send An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/631642
Table of Contents
1 Table of Contents 10
1.1 List of Tables 15
1.2 List of Figures 21
2 Introduction 23
2.1 Catalyst 23
2.2 Related Reports 23
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology
24
3.1.1 Pathophysiology 25
3.1.2 Classification 26
3.1.3 Cytogenetic and Molecular
Abnormalities 29
3.2 Prognosis 35
3.3 Quality of Life 36
3.4 Symptoms 37
4 Epidemiology 39
4.1 Disease Background 39
4.2 Risk Factors and Comorbidities
40
4.2.1 Increased age is associated
with increased risk and worsened prognosis 41
4.2.2 Smoking increases the risk
of M2 AML 42
4.2.3 APL is relatively common
among Spanish and Italian origins 42
4.2.4 Chemotherapy and radiation
therapy increases the risk of AML 43
4.2.5 Benzene increases risk of
AML 43
4.3 Global Trends 44
4.3.1 Incidence 44
4.3.2 Survival and Prevalence 46
4.3.3 Subtypes and Mutations 47
4.3.4 Risk Groups 49
4.4 Forecast Methodology 52
4.4.1 Sources Used 53
4.4.2 Forecast Assumptions and
Methods 60
4.4.3 Sources not Used 66
4.5 Epidemiological Forecast for
Acute Myeloid Leukemia (2014-2024) 67
4.5.1 Adjusted Diagnosed Incident
Cases of AML 67
4.5.2 Adjusted Diagnosed Incident
Cases of AML by Age 69
4.5.3 Adjusted Diagnosed Incident
Cases of AML by Sex 70
4.5.4 Age-Standardized Incidence
of AML 72
4.5.5 APL and MDS/tAML 73
4.5.6 APL and MDS/tAML by Age 76
4.5.7 Diagnosed Incident Cases of
AML with FLT3 Mutations 78
4.5.8 Diagnosed Incident Cases of
AML by Risk Group Classifications 79
4.5.9 Five-Year Diagnosed
Prevalent Cases of AML 83
4.5.10 Five-Year Diagnosed
Prevalent Cases of AML by Age 84
4.5.11 Five-Year Diagnosed
Prevalent Cases of APL and MDS/tAML 85
4.5.12 Five-Year Diagnosed
Prevalent Cases of APL and MDS/tAML by Age 87
4.6 Discussion 88
4.6.1 Epidemiological Forecast
Insight 88
4.6.2 Limitations of the Analysis
89
4.6.3 Strengths of the Analysis 90
5 Disease Management 91
5.1 Treatment Overview 91
5.2 Response Criteria and Outcome
Measures 93
5.3 General Treatment Overview 95
5.3.1 Younger AML Patients 97
5.3.2 Older AML Patients 99
5.4 Hematopoietic Stem Cell
Transplant 102
5.5 Monitoring for Residual
Disease 104
5.6 Acute Promyelocytic Leukemia
104
6 Current Treatment Options 107
6.1 Overview 107
6.2 Product Profiles - Major
Brands 110
6.2.1 Cytarabine 110
6.2.2 Dacogen (decitabine) 114
6.2.3 Vidaza (azacitidine) 120
6.2.4 Mylotarg (gemtuzumab
ozogamicin) 128
6.2.5 Other Therapeutic Agents for
AML 135
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment